Prenetics Global Limited and Prof. Dennis Lo announced they have entered into an agreement to establish a joint venture named Insighta. The board of directors of Prenetics Global Limited has unanimously approved the transaction. Transaction Terms - Prenetics will receive a 50% equity stake, while Prof. Lo’s party will also receive a 50% equity stake.

The joint venture will be governed by a six-person board of directors composed of three directors from each side, with Prof. Lo as the Chairman and Danny Yeung as the CEO. The USD 200 million transaction makes it the large private life sciences deal in Hong Kong history and one of the larger in the region. Prenetics will contribute: Robust Capital – Prenetics will provide consideration of USD 100 million, with USD 80 million in cash and USD 20 million in Prenetics stock.

The significant outlay by Prenetics demonstrates a shared belief in Insighta’s potential and will be directly utilized to fast-track clinical trials and commercialization of the breakthrough early cancer detection technology. Strong Management and Commercialization – Danny Yeung, esteemed serial entrepreneur and the dynamic force behind Prenetics, will extend his leadership role as CEO to Insighta. Danny's proven track record positions him perfectly for steering Insighta's journey ahead.

Baker McKenzie is serving as legal advisor to Prenetics. Kwok Yih & Chan is serving as legal advisor to Prof. Lo. About Insighta.